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Cytomegalovirus (CMV*), the first reported transplant-
associated opportunistic virus (1), has remained the most 
frequent single cause or co-cause ofinfections throughout the 
ensuing three decades (2). Because prophylactic drug and 
hyperimmune globulin therapy has not been effective in 
these CMV-infected patients (2-4), Rubin (5) suggested with-
holding treatment until the phase of rapid viral replication 
(preemptive therapy). Early diagnosis of CMV infection, 
upon which this strategy depends, can be accomplished in the 
presymptomatic phase (6, 7) with a rapid quantitative direct 
demonstration of CMV antigen pp65 in cytospin preparations 
of peripheral blood leukocytes (PBL) (8, 9). This method has 
aided in the management of 20 CMV seronegative recipients 
of livers from seropositive donors, a circumstance that carries 
an 85-90% risk of virus transmission of CMV disease, pre-
sumably from migratory monocytes from the graft (10) that 
are known to harbor the latent virus in healthy seropositive 
individuals (1]). 
The 20 recipients under tacrolimus/prednisone immuno-
suppression were followed for 308± 100.5 days (range, 63-520 
days) after transplantation; a death at 63 days unrelated to 
CMV accounted for the only follow-up of <3 months. Hepa-
rinized blood samples were obtained by schedule during the 
first 3 months or when clinically indicated during this period 
and later. The pp65 antigen was detected in duplicate leuko-
cyte spots (2X 105 cells in 200 J.l.lIglass slide) with the tech· 
nique of Van der Bij et a1. (8), using immunofluorescence (2) 
instead of immunoperoxidase staining (9). The anti·pp65 
mouse monoclonal antibody was clone 1C3 (Hiosoft, Argene, 
France). Fluorescein·isothiocyanate-Iabeled goat anti·mouse 
Fab2 fragment (Cappel, Durham, NC) was applied as the 
conjugate. Slides were counterstained with Evans blue dye 
and observed under 400 x magnification for the typical green 
nuclear fluorescence. 
/\. conventional shell vial culture assay was done on the 
same blood specimens. Anti·CMV antibodies (lgG and IgM) 
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were measured before and after transplantation using a 
semiautomated immunofluorescence test (FIAX test system, 
Whittaker Bioproducts, Inc., Walkersville, MD). IgG titers 
>20 were considered positive. CMV IgG was also the routine 
test used for donor screening. 
Intravenous ganciclovir therapy (Cytovene; Syntex Phar-
maceutical Ltd., Palo Alto, CA) was started only with the 
first detection of pp65 antigenemia, and continued until pp65 
clearance. The ganciclovir dose was governed by creatinine 
clearance: >50 mlImin - 5 mg/kg of ganciclovir twice daily, 
10-50 mllmin - 5 mg/kg every 24-48 hr, and <10 mllmin -
5 mg/kg every 48-96 hr. 
As expected, 17 (85%) of the 20 patients had positive pp65 
tests (CMV antigenemia) after a median posttransplant in-
terval of 34 days (range, 9-83 days). Positive shell vial CMV 
cultures (viremia) were obtained at the same time as the first 
antigenemia diagnosis in only 5 of these 17 cases. 
Twelve of the 17 patients were asymptomatic when the 
first positive pp65 test was obtained, including a recipient 
who was diagnosed only 9 days after transplantation (Fig. 1). 
The pp65 levels were generally low: 20±28 (SO) per 2 X 105 
leukocytes. However, 6 of the 12 had further rises in anti· 
genemia for 1 to 12 days after therapy was started, to a 
median peak of73 stained PBLs (range, 29-446 PBLs), before 
antigenemia began to clear. An example is shown in Figure l. 
Ganciclovir instituted at the time of the first antigenemia 
prevented clinical disease in 11 of the 12 infected patients: 
the exceptional patient had a transient fever. The five other 
patients had CMV hepatitis at the time antigenemia was 
detected 12-83 days after surgery (median, 34 days). The 
median number of pp65-positive cells was 475 (range, 177-
872). 
Antigenemia was cleared with intravenous ganciclovir 
therapy in all 17 patients but recurred in 10 (59%) patients 
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FIGURE 1. Preemptive ganciciovir treatment guided with CMV an-
tigenemia in an asymptomatic. previously seronegative liver trans-
plantation reCIpient whose donor was C;\rv pOSItive. 
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5-174 days (median, 57 days) after the drug had been discon-
tinued. Recurrence was independent of IgG conversion 
(P=0.26). The only patient who was symptomatic with recur-
rence had 430 pp65-stained cells, which cleared after re-
sumption of ganciclovir. The nine asymptomatic patients had 
3-101 pp65-stained cells. Ganciclovir retreatment promptly 
cleared the antigenemia in the recipient with 101 stained 
cells. Retreatment was withheld in the other eight patients 
whose samples had <100 stained cells, and the antigenemia 
resolved spontaneously in all. 
In these cases, the antigen assay was useful as a signal to 
begin preemptive antiviral treatment, as envisioned by Ru-
bin (2), as a means to decide whether to reinstitute ganciclo-
vir in the event of a recurrence (previously emphasized by 
The et al. (6]) and as a guide to individualize the duration of 
a ganciclovir course in all of these circumstances. The assay 
also can be an important differential diagnostic tool. The 
persistence of symptoms despite clearance of the CMV pp65 
antigen is an unambiguous warning of co-infection by an-
other pathogen. Conversely, failure of antigen clearance 
should raise suspicion of ganciclovir-resistant CMV mutants. 
The pp65 findings are specific. With a novel method for 
quantitation of CMV DNA in leukocytes, a highly significant 
correlation was demonstrated between leukoDNAemia and 
the presence and quantity of pp65 antigenemia (13). 
The sensitivity and quantitation nature of the pp65 test 
allowed new observations about response to therapy, such as 
the reason for increases in pp65 levels seen during the first 
few days after beginning ganciclovir in half of the preemp-
tively treated patients. This may have reflected a delay in 
suppression of viral replication or, alternatively, phagocyto-
sis by PBLs of degrading CMV matrix protein from lysed, 
infected leukocytes (14) or from the ballooned and infected 
endothelial cells that shed into the circulation (15). 
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